Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges

Bashdar Mahmud Hussen; Mohammed Fatih Rasul; Snur Rasool Abdullah; Hazha Jamal Hidayat; Goran Sedeeq Hama Faraj; Fattma Abodi Ali; Abbas Salihi; Aria Baniahmad; Soudeh Ghafouri-Fard; Milladur Rahman; Mark C. Glassy; Wojciech Branicki; Mohammad Taheri

doi:10.1186/s40779-023-00468-6

Your Location：

Home >

Browse articles >

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges

REVIEW | Updated：2025-12-13

- Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges
- Military Medical Research Vol. 11, Issue 3, Pages: 345-373(2024)
- Affiliations：
  
  1.Department of Biomedical Sciences, Cihan University-Erbil, Erbil, Kurdistan Region 44001, Iraq
  2.Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region 44001, Iraq
  3.Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International University, Erbil, Kurdistan Region 44001, Iraq
  4.Medical Laboratory Science, Lebanese French University, Erbil, Kurdistan Region 44001, Iraq
  5.Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Kurdistan Region 44001, Iraq
  6.Department of Medical Laboratory Science, Komar University of Science and Technology, Sulaymaniyah 46001, Iraq
  7.Department of Medical Microbiology, College of Health Sciences, Hawler Medical University, Erbil, Kurdistan Region 44001, Iraq
  8.Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region 44001, Iraq
  9.Center of Research and Strategic Studies, Lebanese French University, Erbil 44001, Iraq
  10.Institute of Human Genetics, Jena University Hospital, 07747 Jena, Germany
  11.Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 374-37515, Iran
  12.Department of Clinical Sciences, Malmö, Section for Surgery, Lund University, 22100 Malmö, Sweden
  13.Translational Neuro-Oncology Laboratory, San Diego (UCSD) Moores Cancer Center, University of California, San Diego, CA 94720, USA
  14.Faculty of Biology, Institute of Zoology and Biomedical Research, Jagiellonian University, 31-007 Kraków, Poland
  15.Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran 374-37515, Iran
- Author bio：
  
  *wojciech.branicki@uj.edu.pl;
  mohammad.taheri@uni-jena.de
- Funds：
- DOI：10.1186/s40779-023-00468-6
  CLC：
- Published：2024-06
- Accepted：
Scan QR Code
Cite this article as: Hussen BM, Rasul MF, Abdullah SR, Hidayat HJ, Faraj GSH, Ali FA, et al. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. Mil Med Res. 2023;10(1):32.
DOI：

Cite this article as: Hussen BM, Rasul MF, Abdullah SR, Hidayat HJ, Faraj GSH, Ali FA, et al. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. Mil Med Res. 2023;10(1):32. DOI： 10.1186/s40779-023-00468-6.

摘要

Abstract

Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade. In the study of cancer

the CRISPR/CRISPR-associated protein (Cas) system opens new avenues into issues that were once unknown in our knowledge of the non-coding genome

tumor heterogeneity

and precision medicines. CRISPR/Cas-based gene-editing technology now allows for the precise and permanent targeting of mutations and provides an opportunity to target small non-coding RNAs such as microRNAs (miRNAs). However

the development of effective and safe cancer gene editing therapy is highly dependent on proper design to be innocuous to normal cells and prevent introducing other abnormalities. This study aims to highlight the cutting-edge approaches in cancer-gene editing therapy based on the CRISPR/Cas technology to target miRNAs in cancer therapy. Furthermore

we highlight the potential challenges in CRISPR/Cas-mediated miRNA gene editing and offer advanced strategies to overcome them.

关键词

Keywords

references

Ishino Y , Shinagawa H , Makino K , Amemura M , Nakata A . Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product . J Bacteriol . 1987 ; 169 ( 12 ): 5429 – 33 .

Bhaya D , Davison M , Barrangou R . CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation . Annu Rev Genet . 2011 ; 45 ( 1 ): 273 – 97 .

Brouns SJ , Jore MM , Lundgren M , Westra ER , Slijkhuis RJ , Snijders AP , et al . Small CRISPR RNAs guide antiviral defense in prokaryotes . Science . 2008 ; 321 ( 5891 ): 960 – 4 .

Makarova KS , Wolf YI , Alkhnbashi OS , Costa F , Shah SA , Saunders SJ , et al . An updated evolutionary classification of CRISPR-Cas systems . Nat Rev Microbiol . 2015 ; 13 ( 11 ): 722 – 36 .

Rasul MF , Hussen BM , Salihi A , Ismael BS , Jalal PJ , Zanichelli A , et al . Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy . Mol Cancer . 2022 ; 21 ( 1 ): 64 .

Jinek M , Chylinski K , Fonfara I , Hauer M , Doudna JA , Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity . Science . 2012 ; 337 ( 6096 ): 816 – 21 .

Mojica FJM , Díez-Villaseñor C , García-Martínez J , Almendros C . Short motif sequences determine the targets of the prokaryotic CRISPR defence system . Microbiology . 2009 ; 155 ( Pt 3 ): 733 – 40 .

Iacomino G . miRNAs: the road from bench to bedside . Genes . 2023 ; 14 ( 2 ): 314 .

Martinez-Lage M , Puig-Serra P , Menendez P , Torres-Ruiz R , Rodriguez-Perales S . CRISPR/Cas9 for cancer therapy: hopes and challenges . Biomedicines . 2018 ; 6 ( 4 ): 105 .

Miyoshi J , Zhu Z , Luo A , Toden S , Zhou X , Izumi D , et al . A microRNA based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study . Mol Cancer . 2022 ; 21 ( 1 ): 44 .

Krol J , Loedige I , Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay . Nat Rev Genet . 2010 ; 11 ( 9 ): 597 – 610 .

Peng Y , Croce CM . The role of microRNAs in human cancer . Signal Transduct Target Ther . 2016 ; 1 : 15004 .

Hussen BM , Hidayat HJ , Salihi A , Sabir DK , Taheri M , Ghafouri-Fard S . MicroRNA: a signature for cancer progression . Biomed Pharmacother . 2021 ; 138 : 111528 .

Liang L , Cen H , Huang J , Qin A , Xu W , Wang S , et al . The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy . Mol Cancer . 2022 ; 21 ( 1 ): 186 .

Shen P , Yang T , Chen Q , Yuan H , Wu P , Cai B , et al . CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing . Mol Cancer . 2021 ; 20 ( 1 ): 51 .

Nombela P , Miguel-López B , Blanco S . The role of m6A, m5C and Ψ RNA modifications in cancer: novel therapeutic opportunities . Mol Cancer . 2021 ; 20 ( 1 ): 18 .

Taghavipour M , Sadoughi F , Mirzaei H , Yousefi B , Moazzami B , Chaichian S , et al . Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis . Cell Biosci . 2020 ; 10 ( 1 ): 12 .

Kang M , Tang B , Li J , Zhou Z , Liu K , Wang R , et al . Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA . Mol Cancer . 2020 ; 19 ( 1 ): 143 .

Leichter AL , Sullivan MJ , Eccles MR , Chatterjee A . MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours . Mol Cancer . 2017 ; 16 ( 1 ): 15 .

Chan SH , Wang LH . Regulation of cancer metastasis by microRNAs . J Biomed Sci . 2015 ; 22 ( 1 ): 9 .

Bhat AA , Younes SN , Raza SS , Zarif L , Nisar S , Ahmed I , et al . Role of noncoding RNA networks in leukemia progression, metastasis and drug resistance . Mol Cancer . 2020 ; 19 ( 1 ): 57 .

Wang Y , Wang L , Chen C , Chu X . New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications . Mol Cancer . 2018 ; 17 ( 1 ): 22 .

Dexheimer PJ , Cochella L . MicroRNAs: from mechanism to organism . Front Cell Dev Biol . 2020 ; 8 : 409 .

De Rie D , Abugessaisa I , Alam T , Arner E , Arner P , Ashoor H , et al . An integrated expression atlas of miRNAs and their promoters in human and mouse . Nat Biotechnol . 2017 ; 35 ( 9 ): 872 – 8 .

Kim YK , Kim VN . Processing of intronic microRNAs . Embo J . 2007 ; 26 ( 3 ): 775 – 83 .

Dastmalchi N , Safaralizadeh R , Banan Khojasteh SM , Sam MR , Latifi-Navid S , Hussen BM , et al . An updated review of the cross-talk between microRNAs and epigenetic factors in cancers . Curr Med Chem . 2021 ; 28 ( 42 ): 8722 – 32 .

Tanzer A , Stadler PF . Molecular evolution of a microRNA cluster . J Mol Biol . 2004 ; 339 ( 2 ): 327 – 35 .

Bohnsack MT , Czaplinski K , Gorlich D . Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs . RNA . 2004 ; 10 ( 2 ): 185 – 91 .

Carthew RW , Sontheimer EJ . Origins and mechanisms of miRNAs and siRNAs . Cell . 2009 ; 136 ( 4 ): 642 – 55 .

Eulalio A , Huntzinger E , Nishihara T , Rehwinkel J , Fauser M , Izaurralde E . Deadenylation is a widespread effect of miRNA regulation . RNA . 2009 ; 15 ( 1 ): 21 – 32 .

Wilczynska A , Bushell M . The complexity of miRNA-mediated repression . Cell Death Differ . 2015 ; 22 ( 1 ): 22 – 33 .

Xu W , San Lucas A , Wang Z , Liu Y . Identifying microRNA targets in different gene regions . BMC Bioinf . 2014 ; 15 : S4 .

Valinezhad Orang A , Safaralizadeh R , Kazemzadeh-Bavili M . Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation . Int J Genomics . 2014 ; 2014 : 970607 .

Zhang Y , Fan M , Zhang X , Huang F , Wu K , Zhang J , et al . Cellular micro-RNAs up-regulate transcription via interaction with promoter TATA-box motifs . RNA . 2014 ; 20 ( 12 ): 1878 – 89 .

Monroig-Bosque PDC , Shah MY , Fu X , Fuentes-Mattei E , Ling H , Ivan C , et al . OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers . Sci Rep . 2018 ; 8 ( 1 ): 13106 .

Fu Z , Wang L , Li S , Chen F , Au-Yeung KK-W , Shi C . MicroRNA as an important target for anticancer drug development . Front Pharmacol . 2021 ; 12 : 736323 .

Vasudevan S , Tong Y , Steitz JA . Switching from repression to activation: microRNAs can up-regulate translation . Science . 2007 ; 318 ( 5858 ): 1931 – 4 .

Friedman RC , Farh KK , Burge CB , Bartel DP . Most mammalian mRNAs are conserved targets of microRNAs . Genome Res . 2009 ; 19 ( 1 ): 92 – 105 .

Iacomino G , Siani A . Role of microRNAs in obesity and obesity-related diseases . Genes Nutr . 2017 ; 12 : 23 .

Lui PY , Jin DY , Stevenson NJ . MicroRNA: master controllers of intracellular signaling pathways . Cell Mol Life Sci . 2015 ; 72 ( 18 ): 3531 – 42 .

Gambari R , Brognara E , Spandidos DA , Fabbri E . Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: new trends in the development of miRNA therapeutic strategies in oncology (Review) . Int J Oncol . 2016 ; 49 ( 1 ): 5 – 32 .

Rhim J , Baek W , Seo Y , Kim JH . From molecular mechanisms to therapeutics: understanding microRNA-21 in cancer . Cells . 2022 ; 11 : 18 .

Misso G , Di Martino MT , De Rosa G , Farooqi AA , Lombardi A , Campani V , et al . Mir-34: a new weapon against cancer? . Mol Ther Nucleic Acids . 2014 ; 3 ( 9 ): e195 .

Fuziwara CS , Kimura ET . Insights into regulation of the miR-17-92 cluster of miRNAs in cancer . Front Med . 2015 ; 2 : 64 .

Park SM , Gaur AB , Lengyel E , Peter ME . The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2 . Genes Dev . 2008 ; 22 ( 7 ): 894 – 907 .

Hussen BM , Salihi A , Abdullah ST , Rasul MF , Hidayat HJ , Hajiesmaeili M , et al . Signaling pathways modulated by miRNAs in breast cancer angiogenesis and new therapeutics . Pathol Res Pract . 2022 ; 230 : 153764 .

Ye J , Guo R , Shi Y , Qi F , Guo C , Yang L . miR-155 regulated inflammation response by the SOCS1-STAT3-PDCD4 axis in atherogenesis . Mediators Inflamm . 2016 ; 2016 : 8060182 .

Alexandrov P , Zhai Y , Li W , Lukiw W . Lipopolysaccharide-stimulated, NF-κB-, miRNA-146a- and miRNA-155-mediated molecular-genetic communication between the human gastrointestinal tract microbiome and the brain . Folia Neuropathol . 2019 ; 57 ( 3 ): 211 – 9 .

Kalsotra A , Wang K , Li PF , Cooper TA . MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development . Genes Dev . 2010 ; 24 ( 7 ): 653 – 8 .

Suzuki H , Maruyama R , Yamamoto E , Kai M . Epigenetic alteration and microRNA dysregulation in cancer . Front Genet . 2013 ; 4 : 258 .

Dittmar RL , Sen S . Chapter 4 - microRNAs in exosomes in cancer . In: Chakrabarti DJ , Mitra DS , editors. Cancer and noncoding RNAs . Boston : Academic Press ; 2018 . p. 59 – 78 .

Menon A , Abd-Aziz N , Khalid K , Poh CL , Naidu R . miRNA: a promising therapeutic target in cancer . Int J Mol Sci . 2022 ; 23 ( 19 ): 11502 .

Katti A , Diaz BJ , Caragine CM , Sanjana NE , Dow LE . CRISPR in cancer biology and therapy . Nat Rev Cancer . 2022 ; 22 ( 5 ): 259 – 79 .

Nguyen DD , Chang S . Development of novel therapeutic agents by inhibition of oncogenic microRNAs . Int J Mol Sci . 2017 ; 19 ( 1 ): 65 .

He L , He X , Lim LP , De Stanchina E , Xuan Z , Liang Y , et al . A micro-RNA component of the p53 tumour suppressor network . Nature . 2007 ; 447 ( 7148 ): 1130 – 4 .

Wen D , Danquah M , Chaudhary AK , Mahato RI . Small molecules targeting microRNA for cancer therapy: promises and obstacles . J Control Release . 2015 ; 219 : 237 - 47 .

Trang P , Medina PP , Wiggins JF , Ruffino L , Kelnar K , Omotola M , et al . Regression of murine lung tumors by the let-7 microRNA . Oncogene . 2010 ; 29 ( 11 ): 1580 – 7 .

Daige CL , Wiggins JF , Priddy L , Nelligan-Davis T , Zhao J , Brown D . Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer . Mol Cancer Ther . 2014 ; 13 ( 10 ): 2352 – 60 .

Bader AG , Brown D , Winkler M . The promise of microRNA replacement therapy . Cancer Res . 2010 ; 70 ( 18 ): 7027 – 30 .

Zhang S , Cheng Z , Wang Y , Han T . The risks of miRNA therapeutics: in a drug target perspective . Drug Des Devel Ther . 2021 ; 15 : 721 - 33 .

Jin HY , Gonzalez-Martin A , Miletic AV , Lai M , Knight S , Sabouri-Ghomi M , et al . Transfection of microRNA mimics should be used with caution . Front Genet . 2015 ; 6 : 340 .

Søkilde R , Newie I , Persson H , Borg Å , Rovira C . Passenger strand loading in overexpression experiments using microRNA mimics . RNA Biol . 2015 ; 12 ( 8 ): 787 – 91 .

Ma L , Reinhardt F , Pan E , Soutschek J , Bhat B , Marcusson EG , et al . Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model . Nat Biotechnol . 2010 ; 28 ( 4 ): 341 – 7 .

Gong H , Chen H , Xiao P , Huang N , Han X , Zhang J , et al . miR-146a impedes the anti-aging effect of AMPK via NAMPT suppression and NAD + /SIRT inactivation . Signal Transduct Target Ther . 2022 ; 7 ( 1 ): 66 .

Xu H , Guo S , Li W , Yu P . The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells . Sci Rep . 2015 ; 5 : 12453 .

Su Y , Hou W , Zhang C , Ji P , Hu R , Zhang Q , et al . Long non-coding RNA ZFAS1 regulates cell proliferation and invasion in cervical cancer via the miR-190a-3p/KLF6 axis . Bioengineered . 2022 ; 13 ( 2 ): 3840 – 51 .

Ebert MS , Sharp PA . MicroRNA sponges: progress and possibilities . RNA . 2010 ; 16 ( 11 ): 2043 – 50 .

Ahmadi S , Sharifi M , Salehi R . Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation . Cancer Gene Ther . 2016 ; 23 ( 7 ): 199 – 205 .

De Cola A , Lamolinara A , Lanuti P , Rossi C , Iezzi M , Marchisio M , et al . MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells . Cell Death Dis . 2018 ; 9 ( 8 ): 821 .

Ishida M , Selaru FM . miRNA-based therapeutic strategies . Curr Anesthesiol Rep . 2013 ; 1 ( 1 ): 63 – 70 .

Owczarzy R , You Y , Groth CL , Tataurov AV . Stability and mismatch discrimination of locked nucleic acid-DNA duplexes . Biochemistry . 2011 ; 50 ( 43 ): 9352 – 67 .

Bader AG , Brown D , Stoudemire J , Lammers P . Developing therapeutic microRNAs for cancer . Gene Ther . 2011 ; 18 ( 12 ): 1121 – 6 .

Singh S , Narang AS , Mahato RI . Subcellular fate and off-target effects of siRNA, shRNA, and miRNA . Pharm Res . 2011 ; 28 ( 12 ): 2996 – 3015 .

Takagi S , Nakajima M , Kida K , Yamaura Y , Fukami T , Yokoi T . MicroRNAs regulate human hepatocyte nuclear factor 4α, modulating the expression of metabolic enzymes and cell cycle . J Biol Chem . 2010 ; 285 ( 7 ): 4415 – 22 .

Hong DS , Kang YK , Borad M , Sachdev J , Ejadi S , Lim HY , et al . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours . Br J Cancer . 2020 ; 122 ( 11 ): 1630 – 7 .

Fortunato O , Iorio MV . The therapeutic potential of microRNAs in cancer: illusion or opportunity? . Pharmaceuticals . 2020 ; 13 ( 12 ): 438 .

Chang H , Yi B , Ma R , Zhang X , Zhao H , Xi Y . CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo . Sci Rep . 2016 ; 6 : 22312 .

Huo W , Zhao G , Yin J , Ouyang X , Wang Y , Yang C , et al . Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells . J Cancer . 2017 ; 8 ( 1 ): 57 – 64 .

El Fatimy R , Subramanian S , Uhlmann EJ , Krichevsky AM . Genome editing reveals glioblastoma addiction to microRNA-10b . Mol Ther . 2017 ; 25 ( 2 ): 368 – 78 .

Cyranoski D . CRISPR gene-editing tested in a person for the first time . Nature . 2016 ; 539 ( 7630 ): 479 .

Price C , Chen J . MicroRNAs in cancer biology and therapy: current status and perspectives . Genes Dis . 2014 ; 1 ( 1 ): 53 – 63 .

Jing W , Zhang X , Sun W , Hou X , Yao Z , Zhu Y . CRISPR/CAS9-mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 cells . Biomed Res Int . 2015 ; 2015 : 326042 .

Bala S , Marcos M , Kodys K , Csak T , Catalano D , Mandrekar P , et al . Upregulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor α (TNFα) production via increased mRNA half-life in alcoholic liver disease . J Biol Chem . 2011 ; 286 ( 2 ): 1436 – 44 .

Li Z , Zhou X , Wei M , Gao X , Zhao L , Shi R , et al . In vitro and in vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/dCas9 . Nano Lett . 2018 ; 19 ( 1 ): 19 – 28 .

Narayanan A , Hill-Teran G , Moro A , Ristori E , Kasper DM , Roden AC , et al . In vivo mutagenesis of miRNA gene families using a scalable multiplexed CRISPR/Cas9 nuclease system . Sci Rep . 2016 ; 6 : 32386 .

Zhang YH , Wu LZ , Liang HL , Yang Y , Qiu J , Kan Q , et al . Pulmonary surfactant synthesis in miRNA-26a-1/miRNA-26a-2 double knockout mice generated using the CRISPR/Cas9 system . Am J Transl Res . 2017 ; 9 ( 2 ): 355 – 6 .

Godden AM , Antonaci M , Ward NJ , Van Der Lee M , Abu-Daya A , Guille M , et al . An efficient miRNA knockout approach using CRISPR-Cas9 in Xenopus . Dev Biol . 2022 ; 483 : 66 - 75 .

Senís E , Mockenhaupt S , Rupp D , Bauer T , Paramasivam N , Knapp B , et al . TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus . Nucl Acids Res . 2017 ; 45 ( 1 ): e3 .

Wang Z , Sun X , Zhang X , Dong B , Yu H . Development of a miRNA sensor by an inducible CRISPR-Cas9 construct in Ciona embryogenesis . Mol Biotechnol . 2021 ; 63 ( 7 ): 613 – 20 .

Zhang Z , Ursin R , Mahapatra S , Gallicano GI . CRISPR/CAS9 ablation of individual miRNAs from a miRNA family reveals their individual efficacies for regulating cardiac differentiation . Mech Dev . 2018 ; 150 : 10 - 20 .

Michaels YS , Wu Q , Fulga TA . Interrogation of functional miRNA–target interactions by CRISPR/Cas9 genome engineering . In: Dalmay T , editor. MicroRNA detection and target identification . Humana, New York, NY : Springer ; 2017 .p. 79 – 97 .

Matano M , Date S , Shimokawa M , Takano A , Fujii M , Ohta Y , et al . Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids . Nat Med . 2015 ; 21 ( 3 ): 256 – 62 .

Zhao Y , Shi C , Zhao Y , Xin Z , Liu P , Zhang C , et al . Construction of miRNA-29b1 knockout mice based on CRISPR/Cas9 technology . Chin J Comp Med . 2016 ; 26 ( 12 ): 1 – 4 .

Kurata JS , Lin RJ . MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs . RNA . 2018 ; 24 ( 7 ): 966 – 81 .

Lataniotis L , Albrecht A , Kok FO , Monfries CA , Benedetti L , Lawson ND , et al . CRISPR/Cas9 editing reveals novel mechanisms of clustered microRNA regulation and function . Sci Rep . 2017 ; 7 ( 1 ): 8585 .

Voytas DF . Plant genome engineering with sequence-specific nucleases . Annu Rev Plant Biol . 2013 ; 64 : 327 - 50 .

Zhang JP , Li XL , Li GH , Chen W , Arakaki C , Botimer GD , et al . Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage . Genome Biol . 2017 ; 18 ( 1 ): 35 .

Sander JD , Dahlborg EJ , Goodwin MJ , Cade L , Zhang F , Cifuentes D , et al . Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA) . Nat Methods . 2011 ; 8 ( 1 ): 67 – 9 .

Cermak T , Doyle EL , Christian M , Wang L , Zhang Y , Schmidt C , et al . Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting . Nucleic Acids Res . 2011 ; 39 ( 12 ): e82 .

Bin Moon S , Lee JM , Kang JG , Lee N-E , Ha D-I , Kim DY , et al . Highly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3′-overhang . Nat Commun . 2018 ; 9 ( 1 ): 3651 .

Wang JY , Pausch P , Doudna JA . Structural biology of CRISPR–Cas immunity and genome editing enzymes . Nat Rev Microbiol . 2022 ; 20 ( 11 ): 641 – 56 .

Zhang H , Qin C , An C , Zheng X , Wen S , Chen W , et al . Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer . Mol Cancer . 2021 ; 20 ( 1 ): 126 .

Peng S , Tan Z , Chen S , Lei C , Nie Z . Integrating CRISPR-Cas12a with a DNA circuit as a generic sensing platform for amplified detection of microRNA . Chem Sci . 2020 ; 11 ( 28 ): 7362 – 8 .

Anzalone AV , Koblan LW , Liu DR . Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors . Nat Biotechnol . 2020 ; 38 ( 7 ): 824 – 44 .

Gleditzsch D , Pausch P , Müller-Esparza H , Özcan A , Guo X , Bange G , et al . PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures . RNA Biol . 2019 ; 16 ( 4 ): 504 – 17 .

Makarova KS , Wolf YI , Iranzo J , Shmakov SA , Alkhnbashi OS , Brouns SJJ , et al . Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants . Nat Rev Microbiol . 2020 ; 18 ( 2 ): 67 – 83 .

Pelea O , Fulga TA , Sauka-Spengler T . RNA-responsive gRNAs for controlling CRISPR activity: current advances, future directions, and potential applications . CRISPR J . 2022 ; 5 ( 5 ): 642 – 59 .

Nishimasu H , Ran FA , Hsu PD , Konermann S , Shehata SI , Dohmae N , et al . Crystal structure of Cas9 in complex with guide RNA and target DNA . Cell . 2014 ; 156 ( 5 ): 935 – 49 .

Zhao Z , Li C , Tong F , Deng J , Huang G , Sang Y . Review of applications of CRISPR-Cas9 gene-editing technology in cancer research . Biol Proced Online . 2021 ; 23 ( 1 ): 14 .

Jiang F , Zhou K , Ma L , Gressel S , Doudna JA . Structural biology. A Cas9-guide RNA complex preorganized for target DNA recognition . Science . 2015 ; 348 ( 6242 ): 1477 – 81 .

Anders C , Niewoehner O , Duerst A , Jinek M . Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease . Nature . 2014 ; 513 ( 7519 ): 569 – 73 .

Pacesa M , Loeff L , Querques I , Muckenfuss LM , Sawicka M , Jinek M . R-loop formation and conformational activation mechanisms of Cas9 . Nature . 2022 ; 609 ( 7925 ): 191 – 6 .

Globyte V , Lee SH , Bae T , Kim JS , Joo C . CRISPR/Cas9 searches for a protospacer adjacent motif by lateral diffusion . Embo J . 2019 ; 38 ( 4 ): e99466 .

Cofsky JC , Soczek KM , Knott GJ , Nogales E , Doudna JA . CRISPR-Cas9 bends and twists DNA to read its sequence . Nat Struct Mol Biol . 2022 ; 29 ( 4 ): 395 – 402 .

Jiang F , Taylor DW , Chen JS , Kornfeld JE , Zhou K , Thompson AJ , et al . Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage . Science . 2016 ; 351 ( 6275 ): 867 – 71 .

Ivanov IE , Wright AV , Cofsky JC , Aris KDP , Doudna JA , Bryant Z . Cas9 interrogates DNA in discrete steps modulated by mismatches and supercoiling . Proc Natl Acad Sci U S A . 2020 ; 117 ( 11 ): 5853 – 60 .

Cammaerts S , Strazisar M , De Rijk P , Del Favero J . Genetic variants in microRNA genes: impact on microRNA expression, function, and disease . Front Genet . 2015 ; 6 : 186 .

Zhou J , Deng K , Cheng Y , Zhong Z , Tian L , Tang X , et al . CRISPR-Cas9 based genome editing reveals new insights into microRNA function and regulation in rice . Front Plant Sci . 2017 ; 8 : 1598 .

Zhao Y , Dai Z , Liang Y , Yin M , Ma K , He M , et al . Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system . Sci Rep . 2014 ; 4 : 3943 .

Sheng P , Fields C , Aadland K , Wei T , Kolaczkowski O , Gu T , et al . Dicer cleaves 5'-extended microRNA precursors originating from RNA polymerase II transcription start sites . Nucleic Acids Res . 2018 ; 46 ( 11 ): 5737 – 52 .

Abdollah NA , Theva Das K , Narazah M , Abdul Razak SR . Sequence-specific inhibition of microRNA-130a gene by CRISPR/Cas9 system in breast cancer cell line . J Phys Conf Ser . 2017 ; 851 : 012037 . https://doi.org/10.1088/1742-6596/851/1/012037 https://doi.org/10.1088/1742-6596/851/1/012037 .

Park HH , Triboulet R , Bentler M , Guda S , Du P , Xu H , et al . DROSHA knockout leads to enhancement of viral titers for vectors encoding miRNA-adapted shRNAs . Mol Ther Nucleic Acids . 2018 ; 12 : 591 - 9 .

Shmakov S , Smargon A , Scott D , Cox D , Pyzocha N , Yan W , et al . Diversity and evolution of class 2 CRISPR-Cas systems . Nat Rev Microbiol . 2017 ; 15 ( 3 ): 169 – 82 .

Carabias A , Fuglsang A , Temperini P , Pape T , Sofos N , Stella S , et al . Structure of the mini-RNA-guided endonuclease CRISPR-Cas12j3 . Nat Commun . 2021 ; 12 ( 1 ): 4476 .

Tsuchida CA , Zhang S , Doost MS , Zhao Y , Wang J , et al . Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity . Mol Cell . 2022 ; 82 ( 6 ): 1199 – 209 .

Huang CJ , Adler BA , Doudna JA . A naturally DNase-free CRISPR-Cas12c enzyme silences gene expression . Mol Cell . 2022 ; 82 ( 11 ): 2148 – 60.e4 .

Xiao R , Li Z , Wang S , Han R , Chang L . Structural basis for substrate recognition and cleavage by the dimerization-dependent CRISPR-Cas12f nuclease . Nucleic Acids Res . 2021 ; 49 ( 7 ): 4120 – 8 .

Takeda SN , Nakagawa R , Okazaki S , Hirano H , Kobayashi K , Kusakizako T , et al . Structure of the miniature type V-F CRISPR-Cas effector enzyme . Mol Cell . 2021 ; 81 ( 3 ): 558 – 70.e3 .

Pausch P , Soczek KM , Herbst DA , Tsuchida CA , Al-Shayeb B , Banfield JF , et al . DNA interference states of the hypercompact CRISPR–CasΦ effector . Nat Struct Mol Biol . 2021 ; 28 ( 8 ): 652 – 61 .

Li Z , Zhang H , Xiao R , Han R , Chang L . Cryo-EM structure of the RNAguided ribonuclease Cas12g . Nat Chem Biol . 2021 ; 17 ( 4 ): 387 – 93 .

Dong D , Ren K , Qiu X , Zheng J , Guo M , Guan X , et al . The crystal structure of Cpf1 in complex with CRISPR RNA . Nature . 2016 ; 532 ( 7600 ): 522 – 6 .

Swarts DC , Van Der Oost J , Jinek M . Structural basis for guide RNA processing and seed-dependent DNA targeting by CRISPR-Cas12a . Mol Cell . 2017 ; 66 ( 2 ): 221 – 33.e4 .

Stella S , Alcón P , Montoya G . Structure of the Cpf1 endonuclease R-loop complex after target DNA cleavage . Nature . 2017 ; 546 ( 7659 ): 559 – 63 .

Stella S , Mesa P , Thomsen J , Paul B , Alcón P , Jensen SB , et al . Conformational activation promotes CRISPR-Cas12a catalysis and resetting of the endonuclease activity . Cell . 2018 ; 175 ( 7 ): 1856 – 71.e21 .

Zetsche B , Gootenberg JS , Abudayyeh OO , Slaymaker IM , Makarova KS , Essletzbichler P , et al . Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system . Cell . 2015 ; 163 ( 3 ): 759 – 71 .

Huang X , Sun W , Cheng Z , Chen M , Li X , Wang J , et al . Structural basis for two metal-ion catalysis of DNA cleavage by Cas12i2 . Nat Commun . 2020 ; 11 ( 1 ): 5241 .

Swarts DC , Jinek M . Mechanistic insights into the cis- and transacting DNase activities of Cas12a . Mol Cell . 2019 ; 73 ( 3 ): 589 – 600.e4 .

Jiang W , Singh J , Allen A , Li Y , Kathiresan V , Qureshi O , et al . CRISPR-Cas12a nucleases bind flexible dna duplexes without RNA/DNA complementarity . ACS Omega . 2019 ; 4 ( 17 ): 17140 – 7 .

Paul B , Chaubet L , Verver DE , Montoya G . Mechanics of CRISPR-Cas12a and engineered variants on λ-DNA . Nucleic Acids Res . 2022 ; 50 ( 9 ): 5208 – 25 .

Jiang Q , Meng X , Meng L , Chang N , Xiong J , Cao H , et al . Small indels induced by CRISPR/Cas9 in the 5' region of microRNA lead to its depletion and Drosha processing retardance . RNA Biol . 2014 ; 11 ( 10 ): 1243 – 9 .

Chen X . MicroRNA biogenesis and function in plants . FEBS Lett . 2005 ; 579 ( 26 ): 5923 – 31 .

Budak H , Akpinar BA . Plant miRNAs: biogenesis, organization and origins . Funct Integr Genomics . 2015 ; 15 ( 5 ): 523 – 31 .

Ha M , Kim VN . Regulation of microRNA biogenesis . Nat Rev Mol Cell Biol . 2014 ; 15 ( 8 ): 509 – 24 .

Lewis B , Shih IH , Jones-Rhoades M , Bartel D , Burge C . Prediction of mammalian MicroRNA Targets . Cell . 2004 ; 115 : 787 - 98 .

Bartel DP . MicroRNAs: target recognition and regulatory functions . Cell . 2009 ; 136 ( 2 ): 215 – 33 .

Chung PJ , Chung H , Oh N , Choi J , Bang SW , Jung SE , et al . Efficiency of recombinant CRISPR/rCas9-mediated miRNA gene editing in rice . Int J Mol Sci . 2020 ; 21 ( 24 ): 9606 .

Burke JM , Kelenis DP , Kincaid RP , Sullivan CS . A central role for the primary microRNA stem in guiding the position and efficiency of Drosha processing of a viral pri-miRNA . RNA . 2014 ; 20 ( 7 ): 1068 – 77 .

Friedland AE , Tzur YB , Esvelt KM , Colaiácovo MP , Church GM , Calarco JA . Heritable genome editing in C. elegans via a CRISPR-Cas9 system . Nat Methods . 2013 ; 10 ( 8 ): 741 – 3 .

Wu X , Kriz AJ , Sharp PA . Target specificity of the CRISPR-Cas9 system . Quant Biol . 2014 ; 2 ( 2 ): 59 – 70 .

Cao J , Xiao Q , Yan Q . The multiplexed CRISPR targeting platforms . Drug Discov Today Technol . 2018 ; 28 : 53 - 61 .

Ernst MPT , Broeders M , Herrero-Hernandez P , Oussoren E , Van Der Ploeg AT , Pijnappel W . Ready for repair? Gene editing enters the clinic for the treatment of human disease . Mol Ther Methods Clin Dev . 2020 ; 18 : 532 - 57 .

Cullot G , Boutin J , Toutain J , Prat F , Pennamen P , Rooryck C , et al . CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations . Nat Commun . 2019 ; 10 ( 1 ): 1136 .

Kosicki M , Tomberg K , Bradley A . Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements . Nat Biotechnol . 2018 ; 36 ( 8 ): 765 – 71 .

Karvelis T , Bigelyte G , Young JK , Hou Z , Zedaveinyte R , Budre K , et al . PAM recognition by miniature CRISPR-Cas12f nucleases triggers programmable double-stranded DNA target cleavage . Nucleic Acids Res . 2020 ; 48 ( 9 ): 5016 – 23 .

Pausch P , Al-Shayeb B , Bisom-Rapp E , Tsuchida CA , Li Z , Cress BF , et al . CRISPR-CasΦ from huge phages is a hypercompact genome editor . Science . 2020 ; 369 ( 6501 ): 333 – 7 .

Harrington LB , Burstein D , Chen JS , Paez-Espino D , Ma E , Witte IP , et al . Programmed DNA destruction by miniature CRISPR-Cas14 enzymes . Science . 2018 ; 362 ( 6416 ): 839 – 42 .

Strohkendl I , Saifuddin FA , Rybarski JR , Finkelstein IJ , Russell R . kinetic basis for DNA target specificity of CRISPR-Cas12a . Mol Cell . 2018 ; 71 ( 5 ): 816 – 24.e3 .

Kleinstiver BP , Tsai SQ , Prew MS , Nguyen NT , Welch MM , Lopez JM , et al . Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells . Nat Biotechnol . 2016 ; 34 ( 8 ): 869 – 74 .

Kim D , Kim J , Hur JK , Been KW , Yoon SH , Kim JS . Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells . Nat Biotechnol . 2016 ; 34 ( 8 ): 863 – 8 .

Zetsche B , Heidenreich M , Mohanraju P , Fedorova I , Kneppers J , Degennaro EM , et al . Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array . Nat Biotechnol . 2017 ; 35 ( 1 ): 31 – 4 .

Fonfara I , Richter H , Bratovič M , Le Rhun A , Charpentier E . The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA . Nature . 2016 ; 532 ( 7600 ): 517 – 21 .

Kim SK , Kim H , Ahn WC , Park KH , Woo EJ , Lee DH , et al . Efficient transcriptional gene repression by type V-A CRISPR-Cpf1 from eubacterium eligens . ACS Synth Biol . 2017 ; 6 ( 7 ): 1273 – 82 .

Zhang X , Wang J , Cheng Q , Zheng X , Zhao G , Wang J . Multiplex gene regulation by CRISPR-ddCpf1 . Cell Discov . 2017 ; 3 : 17018 .

Cong L , Ran FA , Cox D , Lin S , Barretto R , Habib N , et al . Multiplex genome engineering using CRISPR/Cas systems . Science . 2013 ; 339 ( 6121 ): 819 – 23 .

Hu JH , Miller SM , Geurts MH , Tang W , Chen L , Sun N , et al . Evolved Cas9 variants with broad PAM compatibility and high DNA specificity . Nature . 2018 ; 556 ( 7699 ): 57 – 63 .

Bi H , Fei Q , Li R , Liu B , Xia R , Char SN , et al . Disruption of miRNA sequences by TALENs and CRISPR/Cas9 induces varied lengths of miRNA production . Plant Biotechnol J . 2020 ; 18 ( 7 ): 1526 – 36 .

Paul B , Montoya G . CRISPR-Cas12a: functional overview and applications . Biomed J . 2020 ; 43 ( 1 ): 8 – 17 .

Abels ER , Maas SLN , Nieland L , Wei Z , Cheah PS , Tai E , et al . Glioblastoma-associated microglia reprogramming is mediated by functional transfer of extracellular miR-21 . Cell Rep . 2019 ; 28 ( 12 ): 3105 – 19.e7 .

Van Der Vos KE , Abels ER , Zhang X , Lai C , Carrizosa E , Oakley D , et al . Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain . Neuro Oncol . 2016 ; 18 ( 1 ): 58 – 69 .

Nieland L , Van Solinge TS , Cheah PS , Morsett LM , El Khoury J , Rissman JI , et al . CRISPR-Cas knockout of miR21 reduces glioma growth . Mol Ther Oncolytics . 2022 ; 25 : 121 - 36 .

Gaudelli NM , Komor AC , Rees HA , Packer MS , Badran AH , Bryson DI , et al . Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage . Nature . 2017 ; 551 ( 7681 ): 464 – 71 .

Xie H , Tang L , He X , Liu X , Zhou C , Liu J , et al . SaCas9 requires 5'-NNGRRT-3' PAM for sufficient cleavage and possesses higher cleavage activity than SpCas9 or FnCpf1 in human cells . Biotechnol J . 2018 ; 13 ( 4 ): e1700561 .

Kleinstiver BP , Prew MS , Tsai SQ , Nguyen NT , Topkar VV , Zheng Z , et al . Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition . Nat Biotechnol . 2015 ; 33 ( 12 ): 1293 – 8 .

Pickar-Oliver A , Gersbach CA . The next generation of CRISPR-Cas technologies and applications . Nat Rev Mol Cell Biol . 2019 ; 20 ( 8 ): 490 – 507 .

Chatterjee P , Jakimo N , Jacobson JM . Minimal PAM specificity of a highly similar SpCas9 ortholog . Sci Adv . 2018 ; 4 ( 10 ): eaau0766 .

Yamada M , Watanabe Y , Gootenberg JS , Hirano H , Ran FA , Nakane T , et al . Crystal structure of the minimal Cas9 from Campylobacter jejuni reveals the molecular diversity in the CRISPR-Cas9 systems . Mol Cell . 2017 ; 65 ( 6 ): 1109 – 21.e3 .

Schindele P , Puchta H . Engineering CRISPR/LbCas12a for highly efficient, temperature-tolerant plant gene editing . Plant Biotechnol J . 2020 ; 18 ( 5 ): 1118 .

Kleinstiver BP , Sousa AA , Walton RT , Tak YE , Hsu JY , Clement K , et al . Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing . Nat Biotechnol . 2019 ; 37 ( 3 ): 276 – 82 .

Morisaka H , Yoshimi K , Okuzaki Y , Gee P , Kunihiro Y , Sonpho E , et al . CRISPR-Cas3 induces broad and unidirectional genome editing in human cells . Nat Commun . 2019 ; 10 ( 1 ): 5302 .

Hsu JY , Grünewald J , Szalay R , Shih J , Anzalone AV , Lam KC , et al . Prime-Design software for rapid and simplified design of prime editing guide RNAs . Nat Commun . 2021 ; 12 ( 1 ): 1034 .

Kim HK , Lee S , Kim Y , Park J , Min S , Choi JW , et al . High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells . Nat Biomed Eng . 2020 ; 4 ( 1 ): 111 – 24 .

Kang SH , Lee WJ , An JH , Lee JH , Kim YH , Kim H , et al . Prediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment . Nat Commun . 2020 ; 11 ( 1 ): 3596 .

Zhang XH , Tee LY , Wang XG , Huang QS , Yang SH . Off-target effects in CRISPR/Cas9-mediated genome engineering . Mol Ther Nucleic Acids . 2015 ; 4 : e264 .

Ren X , Yang Z , Xu J , Sun J , Mao D , Hu Y , et al . Enhanced specificity and efficiency of the CRISPR/Cas9 system with optimized sgRNA parameters in drosophila . Cell Rep . 2014 ; 9 ( 3 ): 1151 – 62 .

Matson AW , Hosny N , Swanson ZA , Hering BJ , Burlak C . Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system . PLoS One . 2019 ; 14 ( 12 ): e0226107 .

Gabriel R , Von Kalle C , Schmidt M . Mapping the precision of genome editing . Nat Biotechnol . 2015 ; 33 ( 2 ): 150 – 2 .

Clement K , Rees H , Canver MC , Gehrke JM , Farouni R , Hsu JY , et al . CRISPResso2 provides accurate and rapid genome editing sequence analysis . Nat Biotechnol . 2019 ; 37 ( 3 ): 224 – 6 .

Güell M , Yang L , Church GM . Genome editing assessment using CRISPR genome analyzer (CRISPR-GA) . Bioinformatics . 2014 ; 30 ( 20 ): 2968 – 70 .

Concordet J-P , Haeussler M . CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens . Nucleic Acids Res . 2018 ; 46 ( W1 ): W242 – 5 .

Liu H , Wei Z , Dominguez A , Li Y , Wang X , Qi LS . CRISPR-ERA: a comprehensive design tool for CRISPR-mediated gene editing, repression and activation . Bioinformatics . 2015 ; 31 ( 22 ): 3676 – 8 .

Montague TG , Cruz JM , Gagnon JA , Church GM , Valen E . CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing . Nucleic Acids Res . 2014 ; 42 ( W1 ): W401 – 7 .

Park J , Bae S , Kim JS . Cas-Designer: a web-based tool for choice of CRISPR-Cas9 target sites . Bioinformatics . 2015 ; 31 ( 24 ): 4014 – 6 .

Meier JA , Zhang F , Sanjana NE . GUIDES: sgRNA design for loss-of-function screens . Nat Methods . 2017 ; 14 ( 9 ): 831 – 2 .

Moreno-Mateos MA , Vejnar CE , Beaudoin J-D , Fernandez JP , Mis EK , Khokha MK , et al . CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo . Nat Methods . 2015 ; 12 ( 10 ): 982 – 8 .

Stemmer M , Thumberger T , Del Sol KM , Wittbrodt J , Mateo JL . CCTop: an intuitive, flexible and reliable CRISPR/Cas9 target prediction tool . PLoS One . 2015 ; 10 ( 4 ): e0124633 .

Abadi S , Yan WX , Amar D , Mayrose I . A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action . PLoS Comput Biol . 2017 ; 13 ( 10 ): e1005807 .

Chuai G , Ma H , Yan J , Chen M , Hong N , Xue D , et al . DeepCRISPR: optimized CRISPR guide RNA design by deep learning . Genome Biol . 2018 ; 19 ( 1 ): 80 .

Wong N , Liu W , Wang X . WU-CRISPR: characteristics of functional guide RNAs for the CRISPR/Cas9 system . Genome Biol . 2015 ; 16 ( 1 ): 218 .

Varshney GK , Zhang S , Pei W , Adomako-Ankomah A , Fohtung J , Schaffer K , et al . CRISPRz: a database of zebrafish validated sgRNAs . Nucleic Acids Res . 2016 ; 44 ( D1 ): D822 – 6 .

Zhao G , Li J , Tang Y . AsCRISPR: a web server for allele-specific sgRNA design in precision medicine . CRISPR J . 2020 ; 3 ( 6 ): 512 – 22 .

Chen W , Zhang G , Li J , Zhang X , Huang S , Xiang S , et al . CRISPRlnc: a manually curated database of validated sgRNAs for lncRNAs . Nucleic Acids Res . 2019 ; 47 ( D1 ): D63 – 8 .

Pattanayak V , Lin S , Guilinger JP , Ma E , Doudna JA , Liu DR . High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity . Nat Biotechnol . 2013 ; 31 ( 9 ): 839 – 43 .

Tyumentseva MA , Tyumentsev AI , Akimkin VG . Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cells . PLoS One . 2021 ; 16 ( 11 ): e0259812 .

Basila M , Kelley ML , Smith AVB . Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity . PLoS One . 2017 ; 12 ( 11 ): e0188593 .

Rahdar M , Mcmahon MA , Prakash TP , Swayze EE , Bennett CF , Cleveland DW . Synthetic CRISPR RNA-Cas9-guided genome editing in human cells . Proc Natl Acad Sci U S A . 2015 ; 112 ( 51 ): E7110 – 7 .

Wang X , Wang Y , Wu X , Wang J , Wang Y , Qiu Z , et al . Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors . Nat Biotechnol . 2015 ; 33 ( 2 ): 175 – 8 .

Thomson DW , Bracken CP , Goodall GJ . Experimental strategies for microRNA target identification . Nucleic Acids Res . 2011 ; 39 ( 16 ): 6845 – 53 .

Wu S , Huang S , Ding J , Zhao Y , Liang L , Liu T , et al . Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region . Oncogene . 2010 ; 29 ( 15 ): 2302 – 8 .

Kabadi AM , Ousterout DG , Hilton IB , Gersbach CA . Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector . Nucleic Acids Res . 2014 ; 42 ( 19 ): e147 .

Kato Y , Tabata H , Sato K , Nakamura M , Saito I , Nakanishi T . Adenovirus vectors expressing eight multiplex guide RNAs of CRISPR/Cas9 efficiently disrupted diverse hepatitis B virus gene derived from heterogeneous patient . Int J Mol Sci . 2021 ; 22 ( 19 ): 10570 .

Asmamaw MM . Viral vectors for the in vivo delivery of CRISPR components: advances and challenges . Front Bioeng Biotechnol . 2022 ; 10 : 895713 .

Mout R , Ray M , Lee YW , Scaletti F , Rotello VM . In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges . Bioconjug Chem . 2017 ; 28 ( 4 ): 880 – 4 .

Van Haasteren J , Li J , Scheideler OJ , Murthy N , Schaffer DV . The delivery challenge: fulfilling the promise of therapeutic genome editing . Nat Biotechnol . 2020 ; 38 ( 7 ): 845 – 55 .

Yip BH . Recent advances in CRISPR/Cas9 delivery strategies . Biomolecules . 2020 ; 10 ( 6 ): 839 .

Ricobaraza A , Gonzalez-Aparicio M , Mora-Jimenez L , Lumbreras S , Hernandez-Alcoceba R . High-capacity adenoviral vectors: expanding the scope of gene therapy . Int J Mol Sci . 2020 ; 21 ( 10 ): 3643 .

Ahi YS , Bangari DS , Mittal SK . Adenoviral vector immunity: its implications and circumvention strategies . Curr Gene Ther . 2011 ; 11 ( 4 ): 307 – 20 .

Luo Y , Xu X , An X , Sun X , Wang S , Zhu D . Targeted inhibition of the miR-199a/214 cluster by CRISPR interference augments the tumor tropism of human induced pluripotent stem cell-derived neural stem cells under hypoxic condition . Stem Cells Int . 2016 ; 2016 : 3598542 .

Hu YC . Baculovirus as a highly efficient expression vector in insect and mammalian cells . Acta Pharmacol Sin . 2005 ; 26 ( 4 ): 405 – 16 .

Drobna-Śledzińska M , Maćkowska-Maślak N , Jaksik R , Dąbek P , Witt M , Dawidowska M . CRISPRi for specific inhibition of miRNA clusters and miRNAs with high sequence homology . Sci Rep . 2022 ; 12 ( 1 ): 6297 .

Potter H , Heller R . Transfection by electroporation . Curr Protoc Mol Biol . 2018 ; 121 : 9.3.1-13 .

Lino CA , Harper JC , Carney JP , Timlin JA . Delivering CRISPR: a review of the challenges and approaches . Drug Deliv . 2018 ; 25 ( 1 ): 1234 – 57 .

Dasgupta I , Chatterjee A . Recent advances in miRNA delivery systems . Methods Protoc . 2021 ; 4 ( 1 ): 10 .

Chen F , Alphonse M , Liu Q . Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics . Wiley Interdiscip Rev Nanomed Nanobiotechnol . 2020 ; 12 ( 3 ): e1609 .

Ran F , Cong L , Yan WX , Scott DA , Gootenberg JS , Kriz AJ , et al . In vivo genome editing using Staphylococcus aureus Cas9 . Nature . 2015 ; 520 ( 7546 ): 186 – 91 .

Aquino-Jarquin G . CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic . Nanomedicine . 2019 ; 18 : 428 - 31 .

Chew WL , Tabebordbar M , Cheng JK , Mali P , Wu EY , Ng AH , et al . A multifunctional AAV-CRISPR-Cas9 and its host response . Nat Methods . 2016 ; 13 ( 10 ): 868 – 74 .

Alton EW , Armstrong DK , Ashby D , Bayfield KJ , Bilton D , Bloomfield EV , et al . Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial . Lancet Respir Med . 2015 ; 3 ( 9 ): 684 – 91 .

Behr M , Zhou J , Xu B , Zhang H . In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges . Acta Pharm Sin B . 2021 ; 11 ( 8 ): 2150 – 71 .

Lin Y , Wu J , Gu W , Huang Y , Tong Z , Huang L , et al . Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs . Adv Sci (Weinh) . 2018 ; 5 ( 4 ): 1700611 .

Duan L , Ouyang K , Xu X , Xu L , Wen C , Zhou X , et al . Nanoparticle delivery of CRISPR/Cas9 for genome editing . Front Genet . 2021 ; 12 : 673286 .

Steinmetz NF , Lim S , Sainsbury F . Protein cages and virus-like particles: from fundamental insight to biomimetic therapeutics . Biomater Sci . 2020 ; 8 ( 10 ): 2771 – 7 .

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

CRISPR/Cas9 from bench to bedside: What clinicians need to know before application?

Research on Wheel/Rail Action of Heavy Haul Train

Numerical Simulation of 3D Air-Charging Model of the Heavy Haul Train Air Brake Pipes System

Simulation Analysis on Static Performance of EP Solenoid Valves Based on ANSYS

Research on Driving Equipment Suspension Parameters and the Structures of Locomotives with Motor Elastically Mounted on the Frame

Related Author

Zi-Qing Li

Chao-Hong Li

Related Institution

Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University

Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania

Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University

⁰